Pharmaceutical Preparations · DE · CIK 1023024
Develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses
Comparable business profile · signals at a glance
In the 90 days to Mar 13, 2026: 7 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $227K |
| Mar 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36K |
| Mar 11, 2026 | Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357K |
| Mar 9, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 5,087 | $74.13 | $377K |
| Mar 9, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 3,602 | $74.18 | $267K |
| Mar 6, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 2,121 | $74.22 | $157K |
| Mar 6, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,485 | $75.00 | $111K |
| Mar 5, 2026 | Carey Stephen P.SVP & CFO | Sell | 4,000 | $75.56 | $302K |
| Mar 5, 2026 | Carey Stephen P.SVP & CFO | Sell | 3,312 | $75.42 | $250K |
| Mar 3, 2026 | Walsh Patrick DDirector | Sell | 6,000 | $74.23 | $445K |
| Mar 3, 2026 | Gutwerg OriSVP, GENERICS | Sell | 2,060 | $76.50 | $158K |
| Mar 2, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 417 | $74.00 | $31K |
| Feb 20, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415K |
| Feb 20, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,730 | $77.99 | $135K |
| Feb 19, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 2,084 | $77.53 | $162K |
| Feb 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $76.80 | $38K |
| Feb 12, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 7,032 | $76.55 | $538K |
| Jan 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42K |
| Dec 18, 2025 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $134K |
| Dec 12, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $33K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.